Clinical Trial: Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07308886) titled 'Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)' on Dec. 24.

Brief Summary: Background:

Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. People with weaker immune systems are more likely to get KS. People infected with human immunodeficiency virus (HIV) account for 80% of KS cases in the United States. But KS is harder to treat in people with HIV. CYT107 is a human protein, made in a laboratory, that may help boost immunity in people with HIV-associated KS.

Object...